- Home
- AMBO vs SNOA Comparison
AMBO vs SNOA Comparison
Compare AMBO & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- SNOA
- Stock Information
- Founded
- AMBO 2000
- SNOA 1999
- Country
- AMBO United States
- SNOA United States
- Employees
- AMBO N/A
- SNOA N/A
- Industry
- AMBO Other Consumer Services
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- SNOA Health Care
- Exchange
- AMBO Nasdaq
- SNOA Nasdaq
- Market Cap
- AMBO 5.0M
- SNOA 4.6M
- IPO Year
- AMBO 2010
- SNOA 2007
- Fundamental
- Price
- AMBO $1.47
- SNOA $2.85
- Analyst Decision
- AMBO
- SNOA
- Analyst Count
- AMBO 0
- SNOA 0
- Target Price
- AMBO N/A
- SNOA N/A
- AVG Volume (30 Days)
- AMBO 15.7K
- SNOA 604.4K
- Earning Date
- AMBO 11-29-2024
- SNOA 11-07-2024
- Dividend Yield
- AMBO N/A
- SNOA N/A
- EPS Growth
- AMBO N/A
- SNOA N/A
- EPS
- AMBO N/A
- SNOA N/A
- Revenue
- AMBO $9,163,000.00
- SNOA $13,547,000.00
- Revenue This Year
- AMBO N/A
- SNOA $36.00
- Revenue Next Year
- AMBO N/A
- SNOA $25.26
- P/E Ratio
- AMBO N/A
- SNOA N/A
- Revenue Growth
- AMBO N/A
- SNOA 11.81
- 52 Week Low
- AMBO $1.00
- SNOA $2.52
- 52 Week High
- AMBO $6.30
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- AMBO 47.36
- SNOA 49.12
- Support Level
- AMBO $1.33
- SNOA $2.70
- Resistance Level
- AMBO $1.49
- SNOA $3.60
- Average True Range (ATR)
- AMBO 0.15
- SNOA 0.30
- MACD
- AMBO -0.00
- SNOA 0.03
- Stochastic Oscillator
- AMBO 44.00
- SNOA 28.57
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.